Therapeutic Asset Ratings

124 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Cbx-12 Advanced Malignant Solid Neoplasm	National Cancer Institute (NCI)	P1	CC (41)
Ceralasertib Advanced Malignant Solid Neoplasm	National Cancer Institute (NCI)	P1	CC (41)
Danburstotug Advanced Malignant Solid Neoplasm	Mayo Clinic	P1	CC (41)
Dinaciclib Advanced Malignant Solid Neoplasm	National Cancer Institute (NCI)	P1	CC (41)
Elimusertib Advanced Malignant Solid Neoplasm	National Cancer Institute (NCI)	P1	CC (41)
Epha2-Targeting Dopc-Encapsulated Sirna Advanced Malignant Solid Neoplasm	M.D. Anderson Cancer Center	P1	CC (41)
Fermented Wheat Germ Extract Advanced Malignant Solid Neoplasm	University of California, Davis	P1	CC (41)
IPN 60090 Advanced Malignant Solid Neoplasm	M.D. Anderson Cancer Center	P1	CC (41)
m3814 Advanced Malignant Solid Neoplasm	National Cancer Institute (NCI)	P1	CC (41)
mk-2206 Advanced Malignant Solid Neoplasm	National Cancer Institute (NCI)	P1	CC (41)
Neratinib Advanced Malignant Solid Neoplasm	M.D. Anderson Cancer Center	P1	CC (41)
Riluzole Advanced Malignant Solid Neoplasm	National Cancer Institute (NCI)	P1	CC (41)
RSC-1255 Advanced Malignant Solid Neoplasm	RasCal Therapeutics, Inc.	P1	CC (41)
Sorafenib Advanced Malignant Solid Neoplasm	National Cancer Institute (NCI)	P1	CC (41)
TAK-243 Advanced Malignant Solid Neoplasm	National Cancer Institute (NCI)	P1	CC (41)
Temsirolimus Advanced Malignant Solid Neoplasm	M.D. Anderson Cancer Center	P1	CC (41)
TIPIRACIL Advanced Malignant Solid Neoplasm	Roswell Park Cancer Institute	P1	CC (41)
tr-002 Advanced Malignant Solid Neoplasm	University of California, Davis	P1	CC (41)
Trifluridine Advanced Malignant Solid Neoplasm	Roswell Park Cancer Institute	P1	CC (41)
ALECTINIB Advanced Malignant Solid Neoplasm	OHSU Knight Cancer Institute	Early P1	C (38)
Arimidex Advanced Malignant Solid Neoplasm	OHSU Knight Cancer Institute	Early P1	C (38)
Cobimetinib Advanced Malignant Solid Neoplasm	OHSU Knight Cancer Institute	Early P1	C (38)
Entrectinib Advanced Malignant Solid Neoplasm	OHSU Knight Cancer Institute	Early P1	C (38)
Hyaluronidase zzxf Advanced Malignant Solid Neoplasm	OHSU Knight Cancer Institute	Early P1	C (38)

Showing 101 to 124 of 124 assets

PreviousPage 5 of 5Next